0.10Open0.10Pre Close0 Volume60 Open Interest5.00Strike Price0.00Turnover323.90%IV207.23%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1851Delta0.1923Gamma16.60Leverage Ratio-0.0076Theta0.0001Rho3.07Eff Leverage0.0011Vega
BioAtla Stock Discussion
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has announced a poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The event will take place from November 8–10, 2024, at the George R. Brown ...
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Mee...
*Buys: $Shift4 Payments (FOUR.US)$ , $Molina Healthcare (MOH.US)$ , $Hudson Pacific Properties Inc (HPP.US)$ , $Olaplex (OLPX.US)$ , $BioAtla (BCAB.US)$
*Adds: $Baidu (BIDU.US)$ , $Alibaba (BABA.US)$
*Reduced: $JD.com (JD.US)$ , $TheRealReal (REAL.US)$
*Sold: $HCA Healthcare (HCA.US)$ , $Citigroup (C.US)$ $Sprott Physical Gold Trust (PHYS.US)$ , $Block (SQ.US)$ , $Cigna Group (CI.US)$ , $Advance Auto Parts (AAP.US)$ , $BP PLC (BP.US)$ , ...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bioatla Announces FDA Clearance of Investigational New Drug Application for Ba3361, a Cab-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
No comment yet